Long term followup on original Optune clinical trial
an astounding 20% survival at 15 years (in a small trial). Added 11/23/2020
High compliance with Optune™ linked to greatest survival benefit for glioblastoma
29% 5 year survival in high compliance group compared to 4.5% in control group.(Added 1/26/19)
Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
Read this if you are going to use Optune™ - it will help prevent the most comon problems.
No Unexpected Safety Issues Arise With Tumor Treating Fields in Glioblastoma Patients With Shunts, Pacemakers or Defibrillators
(Added 11/21/17)
Results from the trial for newly diagnoes GBM:
5 year survival rate more than doubles the standard of care! (added 9/24/17)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs. Temozolomide Alone for Glioblastoma
This may become the new standard of care for Glioblastoma multiforme. (added 12/15/15)
FDA Approves Optune for Newly Diagnosed Glioblastoma Patients.
Risk of death reduced by 37%!
Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients
Optune can now be used even if you have a non programmable shunt
New data on how Tumor Treating Fields Works
Optune™ is a unique new form of treatment for brain tumors: it uses Tumor Treating Fields (TTF) to kill dividing cells. These fields are delivered by removable transducer arrays that are placed on the head. Click here for a news video about the Novocure NovoTTF-100A.Click on the links below for more information on Optune™.
![]() |